Evidence map›Paper›PMID 36105074›Full record

ArticleAIDS research and treatment2022

Impact of Motivational Enhanced Adherence Counseling and Point-of-Care Viral Load Monitoring on Viral Load Outcome in Women on Life-Long ART: A Randomized Pilot Study.

Mercy T Mutambanengwe-Jacob, Charles C Maponga, K Rivet Amico, Bernard Ngara, Nonhlanhla Yende-Zuma, Tariro D Chawana, Teacler Nematadzira, Justice F Gumbo, Tendayi Goverayi, Petronella Matibe and 5 more

Open access · goldAbstract read
In one paragraph

Article in AIDS research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Mercy T Mutambanengwe-JacobDepartment of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID https://orcid.org/0000-0002-5114-8449
Charles C MapongaDepartment of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
K Rivet AmicoDepartment of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Bernard NgaraDepartment of Primary Health Care Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Nonhlanhla Yende-ZumaCentre for the AIDS Program of Research in South Africa (CAPRISA), Durban, South Africa.
Tariro D ChawanaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Teacler NematadziraUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Justice F GumboUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Tendayi GoverayiUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Petronella MatibeUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Bernadette V MalundaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Jim AizireDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Taha E TahaDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Mary G FowlerDepartment of Pathology, The Johns Hopkins Medicine, Baltimore, MD, USA.
Lynda Stranix-ChibandaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
University of Zimbabwe · ZWJohns Hopkins University · USCentre for the AIDS Programme of Research in South Africa · ZAUniversity of Michigan · US

Funding

UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
The Johns Hopkins University - Uganda Clinical Trials UnitUM1AI069530 · NIAID · JOHNS HOPKINS UNIVERSITY · PI MARY Glenn Fowler, Philippa Musoke · 2012 to 2026
$34.8M
NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069530
6 · The paper itself

Abstract

We piloted the combined effectiveness of point-of-care viral load monitoring plus motivational enhanced adherence counseling (intervention) compared with routine care (control) in women identified at risk of virologic failure in the PROMOTE study in Zimbabwe. In an unblinded randomized study, consenting women with last viral load ≥200 copies/ml and/or pill count outside 90-110% range were randomized 1 : 1 to receive the intervention or continue routine care, comprising laboratory-based VL monitoring and standard EAC, from trained nurses and counsellors. Viral load was measured 0, 3, 6, and 12 months after enrolment. We compared viral suppression <200 copies/ml at 6 and 12 months between the arms through Fisher's exact test and sought associated factors by logistic regression with a 95% confidence interval (CI). Between December 2018 and July 2019, 50 women were enrolled (25 intervention and 25 controls) and followed until November 2020. At entry, 60% of the women were virally suppressed, 52% intervention

Identifiers

PMID36105074
PMCPMC9467808
OpenAlexW4294643712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.